At week 24, the mean change from baseline of the PsA-modified SHS indicated significantly less progression in patients receiving golimumab 50 mg (−0.16, P = 0.011) as compared with placebo (0.27), as did that of the combined golimumab groups (−0.09, P = 0.015), whereas the difference between golimumab 100 mg (−0.02) and placebo did not reach statistical significance.
1
—
—